Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPYZD 4409 is an ubiquitin-activating enzyme (E1) inhibitor. Blocks degradation of p53 and cyclin D3. Inhibits NF-κB activation and induces cell death associated with ER stress. Displays antitumor effects in a mouse model of leukemia.
M. Wt | 351.67 |
Formula | C14H7ClFN3O5 |
Storage | Store at -20°C |
Purity | ≥98% (HPLC) |
CAS Number | 423148-78-1 |
PubChem ID | 60111983 |
InChI Key | MSYMKEYWUWVZQY-TWGQIWQCSA-N |
Smiles | FC(C=C3)=C(Cl)C=C3N(C(/C1=C\C2=CC=C([N+]([O-])=O)O2)=O)NC1=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
References are publications that support the biological activity of the product.
Xu et al (2010) The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma. Blood 115 2251 PMID: 20075161
Keywords: PYZD 4409, PYZD 4409 supplier, PYZD4409, ubiquitin-activating, enzyme, E1, inhibitors, inhibits, ubiquitylation, ubiquitin, Ubiquitin-activating, Enzyme, Post-translational, Modifications, 4994, Tocris Bioscience
Citations are publications that use Tocris products.
Currently there are no citations for PYZD 4409.
There are currently no reviews for this product. Be the first to review PYZD 4409 and earn rewards!
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.